Leerink Partnrs Lifts Earnings Estimates for AnaptysBio

AnaptysBio, Inc. (NASDAQ:ANAB) – Equities research analysts at Leerink Partnrs boosted their FY2026 earnings estimates for AnaptysBio in a research report issued on Wednesday, October 29th. Leerink Partnrs analyst D. Risinger now anticipates that the biotechnology company will post earnings per share of ($2.49) for the year, up from their previous estimate of ($2.83). The consensus estimate for AnaptysBio’s current full-year earnings is ($6.08) per share. Leerink Partnrs also issued estimates for AnaptysBio’s FY2027 earnings at ($2.06) EPS, FY2028 earnings at $3.25 EPS and FY2029 earnings at $1.65 EPS.

Several other equities research analysts have also recently issued reports on the company. Wedbush raised their target price on AnaptysBio from $45.00 to $70.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of AnaptysBio in a report on Wednesday, October 8th. Stifel Nicolaus boosted their price objective on shares of AnaptysBio from $55.00 to $80.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. JPMorgan Chase & Co. upped their target price on shares of AnaptysBio from $42.00 to $80.00 and gave the company an “overweight” rating in a research report on Thursday, July 24th. Finally, UBS Group reiterated a “neutral” rating and set a $20.00 price target (up from $18.00) on shares of AnaptysBio in a research report on Tuesday, August 12th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $57.30.

AnaptysBio Stock Performance

ANAB stock opened at $34.74 on Monday. AnaptysBio has a one year low of $12.21 and a one year high of $38.38. The firm has a market cap of $972.72 million, a PE ratio of -7.75 and a beta of 0.16. The firm’s 50 day moving average price is $27.75 and its 200-day moving average price is $24.37.

AnaptysBio (NASDAQ:ANAB) last posted its earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 earnings per share for the quarter, beating the consensus estimate of ($1.06) by $1.58. The company had revenue of $76.32 million for the quarter, compared to analyst estimates of $15.83 million. AnaptysBio had a negative net margin of 107.66% and a negative return on equity of 366.98%.

Institutional Investors Weigh In On AnaptysBio

Several institutional investors have recently modified their holdings of the company. US Bancorp DE grew its stake in shares of AnaptysBio by 126.5% during the first quarter. US Bancorp DE now owns 1,753 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 979 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in AnaptysBio by 175.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock worth $48,000 after buying an additional 1,377 shares during the last quarter. Osaic Holdings Inc. boosted its position in shares of AnaptysBio by 11,630.0% during the 2nd quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock worth $52,000 after acquiring an additional 2,326 shares in the last quarter. Brooklyn Investment Group boosted its position in shares of AnaptysBio by 1,779.9% during the 1st quarter. Brooklyn Investment Group now owns 6,373 shares of the biotechnology company’s stock worth $118,000 after acquiring an additional 6,034 shares in the last quarter. Finally, Covestor Ltd increased its holdings in shares of AnaptysBio by 131,540.0% in the 3rd quarter. Covestor Ltd now owns 6,582 shares of the biotechnology company’s stock valued at $201,000 after acquiring an additional 6,577 shares during the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.